Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Bicycle Therapeutics plc is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 109 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $46.91 |
|---|---|
| 52-week range | $20.67 - $62.08 |
| 50-day moving average | $55.64 |
| 200-day moving average | $40.83 |
| Wall St. target price | $73.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $46.91 from 2022-01-24
| 1 week (2022-01-18) | 0.56% |
|---|---|
| 1 month (2021-12-23) | -22.17% |
| 3 months (2021-10-25) | -12.58% |
| 6 months (2021-07-23) | 32.85% |
| 1 year (2021-01-25) | 73.87% |
|---|---|
| 2 years (2020-01-24) | 336.37% |
| 3 years (2019-01-21) | N/A |
| 5 years (2017-01-21) | N/A |
| Revenue TTM | $11.8 million |
|---|---|
| Gross profit TTM | $-22,759,000 |
| Return on assets TTM | -17.9% |
| Return on equity TTM | -47.23% |
| Profit margin | 0% |
| Book value | $6.67 |
| Market capitalisation | $1.4 billion |
TTM: trailing 12 months
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $20.6701 up to $62.075. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is -0.2565. This would suggest that Bicycle Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bicycle Therapeutics has bucked the trend.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.